1. Scrip
  2. >>Business

Deal Watch: Millendo Completes Merger With OvaScience, With $85m In Bank For Two Mid-Stage Programs

 
• By Joseph Haas, Eleanor Malone, Sten Stovall, Jo Shorthouse, and Ian Haydock

OvaScience’s cash plus a $49.5m venture capital raise leave Millendo with more than enough to get two current programs to data readouts in early 2020, company says. AMAG merges with Perosphere, adding to its hematology business.

DealWatch_1200x675

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions.

Millendo Therapeutics Inc. succeeded in going public Dec. 7, as its reverse-merger with OvaScience Inc. took effect in tandem with a private financing that brings the new company...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business